The value of osteopontin in the assessment of bone mineral density status in postmenopausal women

Journal of Investigative Medicine

Volumn 61, Issue 1, 2013, Pages 15-21

  Fodor, Daniela ^a   Bondor, Cosmina ^b   Albu, Adriana ^a   Simon, Siao Pin ^c   Craciun, Alexandra ^d   Muntean, Laura ^c,d  

^a 2nd Internal Medicine Department   (Romania)

^b Medical Informatics and Statistical Dept   (Romania)

^c Rheumatology Department   (Romania)

^d IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Bone mineral density; Bone turnover markers; Osteopontin; Osteoporotic vertebral fracture; Vitamin D

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; OSTEOPONTIN; TRIACYLGLYCEROL; VITAMIN D;

AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; FEMALE; FEMUR NECK; GLUCOSE BLOOD LEVEL; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPINE FRACTURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84873688688     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3182761264     Document Type: Article

References (40)

1. Chen J, Singh K, Mukherjee BB, et al. Developmental expression of osteopontin (OPN) mRNA in rat tissues: evidence for a role for OPN in bone formation and resorption. Matrix. 1993;13:113-123.
2. Giachelli CM, Schwartz SM, Liaw L. Molecular and cellular biology of osteopontin: potential role in cardiovascular disease. Trends Cardiovasc Med. 1995;5:88-95.
3. Rittling SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol. 1999;7:103-113.
4. Weber GF, Cantor H. The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev. 1996;7:241-248.
5. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009;3:311-322.
6. McKee MD, Zalzal S, Nanci A. Extracellular matrix in tooth cementum and mantle dentin: localization of osteopontin and other noncollagenous proteins, plasma proteins, and glycoconjugates by electron microscopy. Anat Rec. 1996;245:293-312.
7. Sato M, Morii E, Komori T, et al. Transcriptional regulation of osteopontin gene in vivo by PEBP2alpha A/CBFA1 and ETS1 in the skeletal tissues. Oncogene. 1998;17:1517-1525.
8. Rittling SR, Matsumoto HN, McKee MD, et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res. 1998;13: 1101-1111.
9. Ihara H, Denhardt DT, Furuya K, et al. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem. 2001; 276:13065-13071.
10. Yoshitake H, Rittling SR, Denhardt DT, et al. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A. 1999;96:8156-8160.
11. Franzén A, Hultenby K, Reinholt FP, et al. Altered osteoclast development and function in osteopontin deficient mice. J Orthop Res. 2008;26:721-728.
12. Boskey AL, Maresca M, Ullrich W, et al. Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner. 1993;22:147-159.
13. Nagao M, Feinstein TN, Ezura Y, et al. Sympathetic control of bone mass regulated by osteopontin. Proc Natl Acad Sci U S A. 2011; 108:17767-17772.
14. Shinohara ML, Kim HJ, Kim JH, et al. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc Natl Acad Sci U S A. 2008;105:7235-7239.
15. Thurner PJ, Chen CG, Ionova-Martin S, et al. Osteopontin deficiency increases bone fragility but preserves bone mass. Bone. 2010;46: 1564-1573.
16. Duvall CL, Taylor WR, Weiss D, et al. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. J Bone Miner Res. 2007;22:286-297.
17. Chang IC, Chiang TI, Yeh KT, et al. Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int. 2010;21:1401-1409.
18. Chiang TI, Chang IC, Lee HS, et al. Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment. Osteoporos Int. 2011;22:577-585.
19. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843: 1-129.
20. Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8: 1137-1148.
21. Vordermark D, Said HM, Katzer A, et al. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer. 2006;6:207.
22. Albala C, Yanez M, Devoto E, et al. Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord. 1996; 20:1027-1032.
23. Migliaccio S, Greco EA, Fornari R, et al. Is obesity in women protective against osteoporosis ? Diabetes Metab Syndr Obes. 2011;4:273-282.
24. Gomez-Ambrosi J, Catalan V, Ramirez B, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab. 2007;92:3719-3727.
25. Kiefer FW, Zeyda M, Todoric J, et al. Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology. 2008;149:1350-1357.
26. Kiefer FW, Neschen S, Pfau B, et al. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia. 2011;54:2132-2142.
27. Zeyda M, Gollinger K, Todoric J, et al. Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function. Endocrinology. 2011;152:2219-2227.
28. Biver E, Chopin F, Coiffier G, et al. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis. Joint Bone Spine. 2012;79:20-25.
29. Chubb SA. The measurement of serum CTX. Clin Biochem. 2012;45(12):928-935.
30. Lee J, Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med. 2012;32:105-112.
31. Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391-420.
32. Anderson PH, Atkins GJ, Turner AG, et al. Vitamin D metabolism within bone cells: effects on bone structure and strength. Mol Cell Endocrinol. 2011;347:42-47.
33. Christakos S, Dhawan P, Peng X, et al. New insights into the function and regulation of vitamin D target proteins. J Steroid Biochem Mol Biol. 2007;103:405-410.
34. van Driel M, Pols HA, van Leeuwen JP. Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr Pharm Des. 2004; 10:2535-2555.
35. Atkins GJ, Anderson PH, Findlay DM, et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone. 2007;40:1517-1528.
36. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73-78.
37. Porojnicu AC, Moroti-Constantinescu R, Laslau A, et al. Vitamin D status in healthy Romanian caregivers and risk of respiratory infections. Public Health Nutr. 2012;14:1-6.
38. Rabier B, Héraud A, Grand-Lenoir C, et al. A multicentre, retrospective case-control study assessing the role of trabecular bone score (TBS) in menopausal Caucasian women with low areal bone mineral density (BMDa): analysing the odds of vertebral fracture. Bone. 2010;46: 176-181.
39. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res. 2000;15:183-187.
40. Vasikaran S, Eastell R, Bruyère O, et al. IOF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391-420.